- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
This study is looking at a new medicine for people in the UK with Hodgkin Lymphoma that has come back or hasn't responded to other treatments. It aims to check if the new medicine, AZD7789, is safe, what effects it has, and if it helps in treating the cancer.
For: Relapsed/Refractory Classical Hodgkin LymphomaItaly · Denmark · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors
This study is testing a new medicine, AZD7789, for people with advanced cancers like stomach or lung cancer. It's looking to see if the medicine is safe, how it works in the body, and if it can help shrink tumors.
For: Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma · Advanced or Metastatic Non-small Cell Lung Carcinoma · Advanced or Metastatic Solid TumorsSpain · Netherlands · France